Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $3 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $1 | -$1 | $0 | $3 |
| % Margin | 100% | – | – | 100% |
| R&D Expenses | $27 | $40 | $37 | $26 |
| G&A Expenses | $24 | $26 | $27 | $28 |
| SG&A Expenses | $24 | $26 | $27 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | -$1 | $0 | $0 |
| Operating Expenses | $54 | $65 | $63 | $54 |
| Operating Income | -$53 | -$66 | -$63 | -$52 |
| % Margin | -5,186.2% | – | – | -1,899.1% |
| Other Income/Exp. Net | $23 | -$2 | $0 | -$1 |
| Pre-Tax Income | -$30 | -$68 | -$63 | -$53 |
| Tax Expense | $27 | $0 | $0 | $0 |
| Net Income | -$30 | -$34 | -$31 | -$8 |
| % Margin | -2,920% | – | – | -306.6% |
| EPS | -1.05 | -1.33 | -1.28 | -0.42 |
| % Growth | 21.1% | -3.9% | -204.8% | – |
| EPS Diluted | -1.05 | -1.33 | -1.28 | -0.42 |
| Weighted Avg Shares Out | 28 | 26 | 24 | 20 |
| Weighted Avg Shares Out Dil | 28 | 26 | 24 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $1 | $0 |
| Interest Expense | $5 | $5 | $1 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$51 | -$65 | -$62 | -$52 |
| % Margin | -4,914.7% | – | – | -1,917% |